Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting

At the meeting of the American Society of Clinical Oncology (ASCO 2020), held this year virtually on May 29-31, investigators presented important practice changing findings in non-small cell lung Cancer (NSCLC). In the early-stage resectable NSCLC, the key presentation was ADAURA study. This phase III clinical trial showed that the use of adjuvant osimertinib in stage IB-IIIA NSCLC patients harboring EGFR mutations had a clinically meaningful benefit. In locally advanced NSCLC, the recent studies investigated the role of immune checkpoint inhibitors (ICIs) administred early with or before concurrent chemoradiotherapy. In advanced-stage NSCLC with driver mutations, new targets and drugs were explored. The major step forward was the approval of personalized treatment in very uncommon genomic alterations, as RET fusions or MET mutations. In advanced NSCLC without targetable mutations, some new immunotherapy combination strategies have been presented. One of such combination was tiragolumab, an immune checkpoint inhibitor binding to TIGIT, evaluated with atezolizumab. There were also data from the Checkmate 227 and Checkmate 9LA trials that led to recent approvals.